I'm Netflix shares they are lower despite beats on the top and the bottom lines. The streaming giant warning on lower operating margins in the second half of this year. Let's bring in our Julia Borston with much much more in the quarter.Julia, hey that's right, Frank. Netflix did top earnings expectations and it raised his fullear revenue outlook which was expected and that was bolstered as expected by foreign exchange. But today the stock is down nearly 5%.One factor perhaps weighing on the stocks, the com ...

Uh Kevin, I want to come to you. Any quick thought on meta and also I want to go to your cover call in Nvidia. Kind of walk us through that trade.I mean just real briefly, they you guys covered Meta perfectly. It's was our top pick coming into the year. It remains that way.Time will tell from an AI standpoint, but don't forget the hardware. Don't forget what they're doing with advertising, how they're monetizing AI in advertising specifically. Margins are just going higher.I think the numbers are going to b ...

Analyst's Disclosure:I/we have a beneficial long position in the shares of JEPQ either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any in ...

morning. Thank you for joining the show. >> Thank you for having me.>> All right. So when we're talking about options, I want to start off with just your general thesis. You say investors, if they want to hedge some potential volatility they should look at out of the money options.Just explain that strategy. >> Yeah. Right now the markets are quite complacent.The VIX is around 17%. You look at the VIX futures curve. It's quite steep which really means that the front month futures meaning the 30 day VIX expe ...

Live Chat on The Biotech Forum has been dominated by discussion of covered call opportunities in recent quarters. To see what I and the other season biotech investors are targeting as trading ideas in real-time, just initiate your free trial into The Biotech Forum by clicking HERE .Today, I am putting Twist Bioscience Corporation (NASDAQ: TWST ) in the spotlight for the first time in 2025. The company has posted a couple of additional quarters of results since my article on this small-cap concern. Managemen ...

Group 1 - The Conservative Income Portfolio aims to target the best value stocks with high margins of safety while reducing volatility through well-priced options [1][2] - The Enhanced Equity Income Solutions Portfolio is designed to generate yields of 7-9% while minimizing volatility [1] - Trapping Value provides Covered Calls, focusing on lower volatility income investing and capital preservation, while the Fixed Income Portfolio emphasizes high income potential and significant undervaluation [1][2] Group 2 - Trapping Value consists of a team of analysts with over 40 years of combined experience in generating options income and capital preservation [2] - The investing group operates the Conservative Income Portfolio in collaboration with Preferred Stock Trader, featuring two income-generating portfolios and a bond ladder [2]

Group 1 - The Conservative Income Portfolio targets value stocks with high margins of safety and aims to reduce volatility using well-priced options [1] - The Enhanced Equity Income Solutions Portfolio is designed to generate yields of 7-9% while minimizing volatility [1] - The Covered Calls Portfolio focuses on lower volatility income investing with an emphasis on capital preservation [2] Group 2 - Trapping Value is a team of analysts with over 40 years of combined experience in generating options income while prioritizing capital preservation [3] - The investing group operates the Conservative Income Portfolio in partnership with Preferred Stock Trader, featuring two income-generating portfolios and a bond ladder [3] - The fixed income portfolio aims to buy securities with high income potential and significant undervaluation compared to peers [2]

Group 1 - The article expresses skepticism towards newer "income" funds that utilize covered call strategies, suggesting that these strategies may not be very profitable and could compromise long-term investment goals [1] - The focus is on long-term investment strategies, particularly through low-risk ETFs and CEFs, indicating a preference for stable investment vehicles [1] - The author has nearly ten years of experience in trading stocks and currencies and currently manages a family fund, highlighting a background in diverse investment areas including real estate [1] Group 2 - There is a disclosure of a beneficial long position in the shares of DIVO, indicating a personal investment interest in this specific stock [2] - The article emphasizes that past performance does not guarantee future results, which is a common disclaimer in investment discussions [3] - It is noted that the views expressed may not reflect those of Seeking Alpha as a whole, indicating a level of independence in the analysis presented [3]

The last time I wrote about Tesla, Inc. (NASDAQ: TSLA ) I downgraded the stock from a Strong Buy to a Buy. Still, the company's stock surged by about 44%, hitting a high of around $360 before heading south again. Don't Hesitate! Take advantage of the 2-week free trial and receive this limited-time 20% discount with your subscription. Sign up now and start beating the market today! Invest alongside the Financial Prophet's All-Weather Portfolio (2025 H1 23% return) and achieve optimal results in any market. T ...

Group 1 - The article highlights Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) as a focus for investment discussions in 2025, particularly in the context of covered call opportunities in the biotech sector [1] - The Biotech Forum, led by Bret, offers a model portfolio featuring 12-20 high upside biotech stocks, along with live chat discussions and weekly research updates [1] - The forum provides market commentary and portfolio updates every weekend, indicating an active engagement with current market trends [1] Group 2 - The article does not provide specific financial metrics or performance data for Aurinia Pharmaceuticals Inc. or the broader biotech industry [2][3]